Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Transposon-engineered BAFF ligand–based CAR T cells induced responses with a tolerable safety profile among 3 patients with relapsed/refractory B-cell NHL.

Transposon-Based BAFF CAR T Cells Show Early Efficacy, Safety in R/R Non-Hodgkin Lymphoma

Nicole Lamanna, MD, highlights various clinical trials underway evaluating new treatment options for patients with chronic lymphocytic leukemia. 

Piecing Together the Proper BTK Usage in CLL

When evaluating real-world experience, differences in race/ethnicity and among elderly patients with DLBCL appeared different from those seen in clinical trials, highlighting the need for consideration in these patient populations.

Real-World Experience With CAR T Varies From Trials in DLBCL

Advancements in FL treatment, including BTK inhibitors and CAR T-cell therapies, offer new hope for relapsed or refractory cases.

BTK Inhibitors, CAR T-Cell Therapy Drive Paradigm Changes in Follicular Lymphoma

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Interactive Tools

Biomarker Consortium

Subscribe

Articles

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Sacituzumab tirumotecan monotherapy demonstrated antitumor activity with a manageable safety profile in previously treated endometrial and ovarian cancers. 

Sacituzumab Tirumotecan Shows Antitumor Activity in Previously Treated Endometrial, Ovarian Cancers

A new study by researchers at Fox Chase Cancer Center and other institutions adds to that body of research, finding that there are significant differences in the microbiomes of patients who developed bladder cancer compared to those who were healthy.

Fox Chase Cancer Center Researchers Find Differences in the Gut Microbiomes of Bladder Cancer Patients

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for 

as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

NXP800 generated antitumor activity as monotherapy in platinum-resistant ovarian cancer harboring ARID1a mutations.

NXP800 Demonstrates Single-Agent Activity in ARID1a+ Platinum-Resistant Ovarian Cancer

Eftilagimod alpha plus pembrolizumb and chemotherapy generated favorable survival data in nonsquamous NSCLC.

Eftilagimod Alpha Plus Pembrolizumab/Chemo Generates Improved Survival Trends in Advanced NSCLC

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

Click below for the latest updates from Allegheny Health Network's Cancer Institute:

AHN Breakthrough